Why the study?
To advocate further research in bioresorbable scaffold technology by evaluating the long-term safety, feasibility, and performance of Absorb BVS in true coronary bifurcations.
Does a self-expanding biolimus-eluting bifurcation device combined with bioresorbable scaffolds improve minimal luminal area compared to a modified-T stenting strategy with bioresorbable scaffolds in patients with true coronary bifurcation lesions?
Does a self-expanding biolimus-eluting bifurcation device combined with bioresorbable scaffolds improve minimal luminal area compared to a modified-T stenting strategy with bioresorbable scaffolds in patients with true coronary bifurcation lesions?
In a small RCT of complex bifurcation stenting, bioresorbable vascular scaffolds showed significant luminal loss and structural discontinuities at 30 months, though clinical outcomes remained acceptable at 5 years.
Answers are grounded in this paper and cite their sources.
Low 5-year event rates support BVS safety in true bifurcations with either strategy; extends follow-up data in this small RCT.
BACKGROUND: In order to advocate further research in bioresorbable scaffold (BVS) technology we report the final 5-year outcomes of the COBRA II study, the only randomized controlled trial (RCT) performed to investigate the safety, feasibility, and performance of Absorb BVS (Abbott Vascular) in true coronary bifurcations. METHODS: COBRA II was a prospective single-center RCT. Fifteen patients with true coronary bifurcation lesions were randomized to bifurcation treatment with self-expanding biolimus-eluting Axxess bifurcation device (Biosensors International) combined with additional bioresorbable everolimus-eluting Absorb BVS in the bifurcation branches on (Axxess group) or to 2-stent mod-T stenting technique with Absorb BVS (mod-T group). Optical coherence tomography was performed post-procedure and at 30-months. The primary endpoint was change in minimal luminal area (MLA) on OCT from baseline to 30-months. RESULTS: Fifteen patients with coronary bifurcation lesions were randomized to the Axxess group (n = 8) or Modified-T group (n = 7). At 30 months, MLAs were significantly smaller than post-procedure in the majority of bifurcation segments treated with BVS due to neointima formation, while MLAs in the proximal Axxess segment remained stable (primary endpoint). Five-year clinical follow-up was available for all patients. Only 1 major adverse cardiac event occurred; a patient underwent target lesion revascularization at 30 months in the Axxess group. There were no cases of cardiac death, spontaneous MI, or stent/scaffold thrombosis. CONCLUSIONS: In this small RCT bifurcation study, BVS luminal dimensions were significantly smaller at 30 months, with acute strut discontinuities and late Intraluminal dismantling frequently observed, although acceptable clinical outcomes were noted at 5 years.
No takes yet. Share an insight, caveat, or question.
Bennett et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: